In 175 probands from a clinic based series of breast and/or ovarian cancer families with no detectable BRCA1/BRCA2 mutations, we have identified two mutations in PALB2: one, c.3113G > A, is known to be deleterious and the other, c.3507_3508delTC (p.H1170Ffs*19), is likely to be deleterious. This evidence concerns the gene BRCA2 and ovarian cancer.